Diaceutics PLC represents a strong commitment to revolutionizing patient testing in the global diagnostic industry. The company's corporate philosophy is rooted in driving better patient outcomes by improving diagnostic testing for precision medicine. With a focus on leveraging data analytics and deep industry knowledge, Diaceutics PLC aims to bridge the gap between diagnostic testing and targeted therapies. By partnering with pharmaceutical companies, laboratories, and healthcare providers, Diaceutics PLC strives to enable faster and more accurate testing to ensure patients receive the right treatment at the right time. Through innovation, collaboration, and patient-centricity, Diaceutics PLC is dedicated to empowering precision medicine and transforming healthcare.

Diaceutics PLC is primarily present in multiple countries and regions worldwide. The company operates globally, with a strong presence in the United States, Europe, and key Asian markets. This includes countries such as the United Kingdom, Germany, France, Spain, Italy, China, Japan, and Australia, among others. With its expansive reach, Diaceutics PLC caters to healthcare providers, pharmaceutical companies, and diagnostic laboratories in various regions, enabling better personalized medicine and improving patient outcomes.

Diaceutics PLC, a leading diagnostic data analytics and implementation services provider, has achieved several significant milestones. Firstly, the company successfully listed on the AIM market of the London Stock Exchange in March 2019, marking a major achievement in terms of financial market recognition. Additionally, Diaceutics has experienced substantial growth, expanding its global reach and establishing strategic partnerships with renowned pharmaceutical companies. Moreover, the company has received multiple awards and recognition for its innovative and impactful contributions to precision medicine. Diaceutics PLC's remarkable achievements are a testament to its commitment to revolutionizing the way healthcare providers utilize diagnostic testing, ultimately improving patient outcomes.

Diaceutics PLC is a leading data analytics and implementation services provider in the personalized medicine industry. Founded in 2005, the company has grown steadily and garnered a strong reputation for its expertise in diagnostic testing. It enables pharmaceutical companies, laboratories, and healthcare providers to optimize the use of targeted therapies for patients by leveraging advanced data analytics. Diaceutics PLC's robust platform helps bridge the gap between diagnostic testing and personalized medicine, significantly improving patient outcomes. With its deep industry knowledge and proprietary data-driven solutions, the company has become a trusted partner for life science companies globally, unlocking the potential of precision medicine.

The main competitors of Diaceutics PLC in the market include companies such as LabCorp, QIAGEN, Foundation Medicine, and Genomic Health.

Diaceutics PLC is primarily active in the healthcare and pharmaceutical industries. As a leading diagnostic commercialization company, Diaceutics specializes in helping pharmaceutical companies and laboratories improve patient outcomes through the delivery of precision medicine. With their extensive expertise in data analytics and laboratory network management, Diaceutics empowers healthcare providers to effectively integrate diagnostic testing into patient treatment pathways, thereby enhancing personalized medicine.

The business model of Diaceutics PLC focuses on providing personalized diagnostics solutions and services to the pharmaceutical industry. Diaceutics helps pharmaceutical companies and laboratories optimize their diagnostic testing processes, ensuring patients receive accurate and timely test results. By harnessing real-world data and leveraging their expertise in diagnostic commercialization, the company enables precision medicine and improves patient outcomes. With a comprehensive approach that includes strategic consulting, data analytics, and software solutions, Diaceutics aims to bridge the gap between diagnostic testing and the delivery of targeted therapies.

Diaceutics의 P/E 비율은 -66.97입니다.

Diaceutics의 P/S 비율은 3.4입니다.

Diaceutics에 대한 AlleAktien 품질 점수는 3/10입니다.

예상되는 Diaceutics 매출은 30.14 백만 GBP입니다.

예상되는 Diaceutics 이익은 -1.53 백만 GBP입니다.

Diaceutics PLC is an international company specializing in improving the diagnostics and care of cancer patients. The company's business model is based on the use of data analysis to understand the connections between diagnostics, therapy, and patient outcomes in order to optimize cancer treatment.

Diaceutics은(는) 연간 번의 배당을 통해 0 GBP의 배당금을 지급합니다.

Diaceutics의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Diaceutics의 ISIN은 GB00BJQTGV64입니다.

Diaceutics의 WKN은 A2PF80입니다.

Diaceutics의 티커는 DXRX.L입니다.

지난 12개월 동안 Diaceutics은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Diaceutics은(는) 0 GBP의 배당금을 지급할 것으로 예상됩니다.

Diaceutics의 현재 배당 수익률은 입니다.

Diaceutics은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Diaceutics은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 GBP의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Diaceutics은 '건강' 섹터에 속합니다.

Diaceutics의 마지막 배당금을 0 GBP만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Diaceutics는 0 GBP를 배당금으로 지급했습니다.

Diaceutics의 배당금은 GBP에 지급됩니다.